I-Corps: Immunomodulatory Patch for Periodontal Regeneration

I-Corps：用于牙周再生的免疫调节贴片

• 批准号: 2238905
• 负责人: Mohammad Mahdi Hasani Sadrabadi
• 金额: $ 5万
• 依托单位: University of California-Los Angeles
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-01 至 2024-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2238905&HistoricalAwards=false
• 关键词: Corps; Immunomodulatory; Patch; Periodontal; Regeneration

The broader impact/commercial potential of this I-Corps project is the development of a dissolvable microneedle patch that provides a sustained release and local delivery of antibiotics. The first application of the proposed technology will be the treatment of periodontitis, a wide-spread oral disease that impacts up to 47.2% of all adults worldwide. Currently, antibiotic products are only used for severe cases of periodontitis due to the high risk of antibiotic-resistant bacterial strains developing from the leakage of product. By utilizing the proposed technology to deliver antibiotics directly to the local tissue, the proposed microneedle patch overcomes retention and leakage issues. In addition, the proposed design requires minimal to no training for application, and may be easily used as a point-of-care treatment. Patients may eventually have direct access to using the patch with a prescription. This would be the first locally delivered antibiotic for at home care to treat periodontitis. This I-Corps project is based on the development of an engineered, dissolvable, microarray delivery platform that provides a sustained release and local delivery of antibiotics aimed at treating periodontal disease. The proposed technology is a dissolvable patch with biodegradable microneedles, offering a point-of-care option for patients to administer antibiotic treatment at their convenience. The proposed patch may prevent regrowth of the bacterial colonies that initially cause periodontitis and encourage gingival tissue regrowth. The patch is applied to gingival tissue where the membrane support is designed to dissolve quickly for a burst release of antibiotics to immediately reduce bacterial content in the microenvironment. The biocompatible and bioresorbable microneedles penetrate and stay in gingival tissue for the sustained release of biomolecules. The goal of the proposed technology is to overcomes the problems of insufficient penetration and local retention as well as antibacterial and immune modulation.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

该 I-Corps 项目更广泛的影响/商业潜力是开发可溶解的微针贴片，可提供抗生素的持续释放和局部递送。该技术的首次应用将是治疗牙周炎，这是一种广泛传播的口腔疾病，影响着全球 47.2% 的成年人。目前，抗生素产品仅用于治疗严重的牙周炎，因为产品泄漏产生抗生素耐药菌株的风险很高。通过利用所提出的技术将抗生素直接输送到局部组织，所提出的微针贴片克服了滞留和渗漏问题。此外，所提出的设计需要很少甚至不需要培训即可应用，并且可以很容易地用作即时治疗。 患者最终可以凭处方直接使用该贴片。 这将是第一种用于家庭护理治疗牙周炎的局部给药抗生素。 该 I-Corps 项目基于工程化、可溶解的微阵列递送平台的开发，该平台提供旨在治疗牙周病的抗生素的持续释放和局部递送。 拟议的技术是一种带有可生物降解微针的可溶解贴片，为患者提供了一种在方便时进行抗生素治疗的即时护理选择。所提出的补片可以防止最初引起牙周炎的细菌菌落的再生，并促进牙龈组织的再生。 该贴片被贴在牙龈组织上，其中的膜支撑被设计成能够快速溶解，从而突然释放抗生素，从而立即减少微环境中的细菌含量。 生物相容性和生物可吸收性微针穿透并停留在牙龈组织中，以持续释放生物分子。 拟议技术的目标是克服渗透和局部保留不足以及抗菌和免疫调节的问题。该奖项反映了 NSF 的法定使命，并通过使用基金会的智力优点和更广泛的影响审查标准进行评估，认为值得支持。